Aperio Group LLC lessened its holdings in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 14.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,133 shares of the medical device company’s stock after selling 1,412 shares during the quarter. Aperio Group LLC’s holdings in NxStage Medical were worth $204,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. SG Americas Securities LLC bought a new stake in shares of NxStage Medical in the 1st quarter worth $140,000. Ameritas Investment Partners Inc. purchased a new position in shares of NxStage Medical in the 1st quarter worth about $148,000. Menta Capital LLC purchased a new position in shares of NxStage Medical in the 1st quarter worth about $212,000. Jane Street Group LLC purchased a new position in shares of NxStage Medical in the 1st quarter worth about $213,000. Finally, PEAK6 Investments L.P. purchased a new position in shares of NxStage Medical in the 1st quarter worth about $214,000. Institutional investors and hedge funds own 92.75% of the company’s stock.
A number of equities analysts recently weighed in on the stock. William Blair downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a report on Monday, August 7th. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Thursday, August 10th. Leerink Swann downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $28.00 to $30.00 in a report on Tuesday, August 22nd. Craig Hallum began coverage on shares of NxStage Medical in a report on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Canaccord Genuity downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target on the stock. in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. The company presently has an average rating of “Hold” and an average target price of $30.25.
Shares of NxStage Medical, Inc. (NASDAQ NXTM) opened at 27.69 on Thursday. The stock’s 50 day moving average price is $27.80 and its 200-day moving average price is $25.85. The stock’s market cap is $1.83 billion. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.03). The company had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. NxStage Medical’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.03) EPS. On average, equities research analysts forecast that NxStage Medical, Inc. will post ($0.05) earnings per share for the current year.
In other news, President Joseph E. Turk, Jr. sold 1,000 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $27.95, for a total value of $27,950.00. Following the completion of the sale, the president now directly owns 73,903 shares of the company’s stock, valued at approximately $2,065,588.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $29.21, for a total value of $102,235.00. Following the completion of the sale, the senior vice president now directly owns 16,270 shares of the company’s stock, valued at $475,246.70. The disclosure for this sale can be found here. Insiders sold a total of 46,100 shares of company stock valued at $1,286,389 over the last three months. Company insiders own 4.70% of the company’s stock.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with our FREE daily email newsletter.